These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
852 related articles for article (PubMed ID: 19447876)
41. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. May M; Siegsmund M; Hammermann F; Loy V; Gunia S Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019 [TBL] [Abstract][Full Text] [Related]
42. Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1. Yamauchi Y; Kohyama T; Takizawa H; Kamitani S; Desaki M; Takami K; Kawasaki S; Kato J; Nagase T Exp Lung Res; 2010 Feb; 36(1):12-24. PubMed ID: 20128678 [TBL] [Abstract][Full Text] [Related]
43. Decreased expression of glutaredoxin 1 is required for transforming growth factor-beta1-mediated epithelial-mesenchymal transition of EpRas mammary epithelial cells. Lee EK; Jeon WK; Chae MY; Hong HY; Lee YS; Kim JH; Kwon JY; Kim BC; Park SH Biochem Biophys Res Commun; 2010 Jan; 391(1):1021-7. PubMed ID: 19968960 [TBL] [Abstract][Full Text] [Related]
44. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. Behnsawy HM; Miyake H; Harada K; Fujisawa M BJU Int; 2013 Jan; 111(1):30-7. PubMed ID: 23107154 [TBL] [Abstract][Full Text] [Related]
45. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293 [TBL] [Abstract][Full Text] [Related]
46. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256 [TBL] [Abstract][Full Text] [Related]
47. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563 [TBL] [Abstract][Full Text] [Related]
48. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597 [TBL] [Abstract][Full Text] [Related]
49. Lefty antagonises TGF-beta1 induced epithelial-mesenchymal transition in tubular epithelial cells. Mariasegaram M; Tesch GH; Verhardt S; Hurst L; Lan HY; Nikolic-Paterson DJ Biochem Biophys Res Commun; 2010 Mar; 393(4):855-9. PubMed ID: 20171171 [TBL] [Abstract][Full Text] [Related]
50. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. Frommer KW; Reichenmiller K; Schutt BS; Hoeflich A; Ranke MB; Dodt G; Elmlinger MW J Mol Endocrinol; 2006 Aug; 37(1):13-23. PubMed ID: 16901920 [TBL] [Abstract][Full Text] [Related]
51. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Moore LD; Isayeva T; Siegal GP; Ponnazhagan S Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771 [TBL] [Abstract][Full Text] [Related]
52. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Li R; Dai H; Wheeler TM; Sayeeduddin M; Scardino PT; Frolov A; Ayala GE Clin Cancer Res; 2009 May; 15(10):3568-73. PubMed ID: 19417030 [TBL] [Abstract][Full Text] [Related]
53. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Di JM; Pang J; Pu XY; Zhang Y; Liu XP; Fang YQ; Ruan XX; Gao X Cancer Genet Cytogenet; 2009 Jul; 192(2):60-7. PubMed ID: 19596255 [TBL] [Abstract][Full Text] [Related]
54. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Lee HS; Kim C; Kim SB; Kim MG; Park D Biochem Biophys Res Commun; 2010 May; 395(4):553-9. PubMed ID: 20398629 [TBL] [Abstract][Full Text] [Related]
55. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142 [TBL] [Abstract][Full Text] [Related]
56. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Kurahashi T; Miyake H; Hara I; Fujisawa M J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676 [TBL] [Abstract][Full Text] [Related]
57. Regulation of extracellular matrix remodeling following transforming growth factor-beta1/epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes. Wilkins-Port CE; Higgins PJ Cells Tissues Organs; 2007; 185(1-3):116-22. PubMed ID: 17587817 [TBL] [Abstract][Full Text] [Related]
58. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444 [TBL] [Abstract][Full Text] [Related]
59. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. Lv ZD; Kong B; Li JG; Qu HL; Wang XG; Cao WH; Liu XY; Wang Y; Yang ZC; Xu HM; Wang HB Oncol Rep; 2013 Jan; 29(1):219-25. PubMed ID: 23129177 [TBL] [Abstract][Full Text] [Related]